Multimodal Optical Imaging Platform for Studying Cellular Metabolism
June 6th, 2025
1.4K views
Utilizing a multimodal platform combining label-free optical imaging modalities, we have developed a protocol for visualizing and quantifying cellular dynamics and metabolism. Through imaging via multiphoton fluorescence, second harmonic generation, and stimulated Raman scattering microscopy, we can generate a holistic overview of the cellular and molecular environment.
Overview
This study presents a multimodal optical imaging platform that allows for the visualization and quantification of cellular dynamics and metabolism. By employing various imaging techniques, we can gain insights into the cellular and molecular environment across different pathologies.
Key Study Components
Area of Science
- Neuroscience
- Cell Biology
- Optical Imaging
Background
- Multimodal microscopy enables the measurement of molecular and metabolic differences.
- It provides a holistic view of pathophysiological changes.
- Applications are expanding in clinical settings, particularly with micro endoscopes.
- Custom-built microscope systems address experimental challenges.
Purpose of Study
- To visualize metabolism, morphology, and molecular composition simultaneously.
- To investigate diseases and the aging process.
- To classify different breast cancer subtypes.
Methods Used
- Multiphoton fluorescence microscopy
- Second harmonic generation microscopy
- Stimulated Raman scattering microscopy
- Label-free bioorthogonal imaging techniques
Main Results
- Significant strides in understanding lipid metabolism in model organisms.
- Identification of spatial heterogeneity in cellular dynamics.
- Classification of breast cancer subtypes using imaging techniques.
- Enhanced visualization of metabolic processes in the brain.
Conclusions
- The multimodal approach is a powerful tool for disease investigation.
- Label-free imaging techniques provide comprehensive insights into cellular environments.
- Future applications may further enhance clinical imaging capabilities.
Frequently Asked Questions
What is multimodal optical imaging?
It is a technique that combines different imaging modalities to provide a comprehensive view of cellular and molecular processes.
How does this study contribute to cancer research?
The study aids in classifying breast cancer subtypes and understanding their metabolic differences.
What are the challenges of using a multimodal microscope?
The complexity of integrating various hardware components poses significant experimental challenges.
What diseases can be studied using this imaging platform?
The platform can be used to investigate various diseases, including cancer and neurodegenerative disorders.
What are the advantages of label-free imaging?
Label-free imaging allows for the observation of cellular processes without the need for fluorescent tags, preserving the natural state of the cells.
Can this technology be applied in clinical settings?
Yes, the development of micro endoscopes has opened avenues for clinical applications of this imaging technology.
Executive Industry Relevance
Multimodal optical imaging platforms that integrate MPF, SHG, and SRS modalities enable simultaneous, label-free quantification of cellular metabolism, morphology, and molecular composition at subcellular resolution. This capability addresses a critical need for high-content, spatially resolved metabolic and structural data in early discovery and translational research, supporting predictive confidence in disease modeling and mechanistic de-risking. The platform's ability to coregister multiple functional readouts from the same biological region enhances portfolio decision-making and risk-adjusted advancement.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables direct visualization and quantification of metabolic activity and molecular heterogeneity in disease-relevant systems.
- Supports mechanistic de-risking by correlating metabolic states with structural and compositional features.
- Facilitates functional target validation through label-free, multiplexed imaging of live cells and tissues.
Screening & Assay Development
- Provides validated, reproducible imaging outputs for quantitative assessment of metabolic and structural biomarkers.
- Supports assay standardization by enabling simultaneous acquisition of multiple modalities from the same sample region.
- Accelerates screening readiness by reducing the need for exogenous labels and minimizing sample perturbation.
Translational & Preclinical Research
- Aligns metabolic and molecular imaging outputs with disease progression and therapeutic response in preclinical models.
- Enables spatial mapping of metabolic heterogeneity relevant to tumor biology and neurodegeneration.
- Supports continuity from discovery through preclinical validation by providing in situ, label-free readouts.
Pipeline & Workflow Integration
This multimodal imaging platform bridges early discovery, lead identification, and preclinical research by delivering multiplexed, quantitative data from intact biological systems.
- Discovery Biology: Integrates hypothesis testing and pathway clarification by correlating metabolic, structural, and compositional data.
- Screening: Delivers reproducible, quantitative imaging outputs suitable for comparative analysis across conditions.
- Analytics: Provides ratiometric and spatially resolved measurements of oxidative stress and lipid unsaturation for robust statistical analysis.
- Translational Research: Enables alignment of imaging biomarkers with disease states and therapeutic outcomes in model systems.
- Enterprise Reuse: Offers a scalable, label-free imaging capability adaptable across diverse biological models and disease areas.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in target and pathway validation.
- Operational Value: Enhances standardization, reproducibility, and scalability of imaging workflows.
- Strategic Value: Improves go/no-go decision-making and capital efficiency by providing high-content, multiplexed data.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of discovery and preclinical programs.
Implementation Considerations
- Requires expertise in advanced optical imaging and multimodal hardware integration.
- Demands specialized instrumentation, including tunable lasers and synchronized detection systems.
- Necessitates cross-team standardization of imaging protocols and data analysis pipelines.
- Adaptation across model systems may require optimization of imaging parameters and sample preparation.
- Complexity of hardware integration and data management may limit throughput in some settings.
Biopharma FAQs
Why does null hypothesis testing matter for ratiometric metabolic imaging?
Null hypothesis testing in ratiometric metabolic imaging enables objective assessment of differences in oxidative stress and lipid unsaturation between healthy and tumor tissues. This statistical rigor supports confident target validation and mechanistic de-risking in early discovery. Reliable hypothesis testing ensures that observed metabolic changes are significant and actionable for portfolio decisions.
How does independent variable isolation fit multimodal imaging workflows?
Isolating independent variables, such as specific laser wavelengths or imaging modalities, allows precise attribution of observed signals to metabolic, structural, or compositional features. This isolation is critical for dissecting complex biological responses and supports robust discovery-stage analysis. It ensures that multiplexed outputs reflect true biological variation rather than technical artifacts.
What do quantitative dependent variable measurements enable in SRS and MPF imaging?
Quantitative measurements of dependent variables, such as redox ratios and lipid unsaturation, enable spatial mapping of metabolic states and molecular composition within tissues. These outputs provide actionable data for comparing disease and control samples, supporting biomarker discovery and translational research. Quantitative imaging enhances predictive confidence in mechanistic studies.
Why are replication requirements critical for cross-functional imaging studies?
Replication ensures that imaging-derived metabolic and structural differences are reproducible across samples and experimental runs. This is essential for cross-functional collaboration, enabling data comparability and integration across discovery, screening, and translational teams. Consistent replication underpins robust portfolio advancement decisions.
What statistical analysis capabilities are required before implementing ratiometric imaging outputs?
Robust statistical analysis, including ratiometric quantification and comparative testing, is required to validate metabolic and molecular imaging outputs. These capabilities ensure that observed differences are significant and support data-driven decision-making in R&D pipelines. Statistical rigor is foundational for translating imaging findings into actionable insights.
